Friday 6 November 2026 Export A’s income statement to Excel — free account

Agilent Technologies, Inc.

Agilent Technologies, Inc.’s revenue for fiscal 2025 (year ended October 2025) was $6.9 billion, up 6.73% from fiscal 2024.

Revenue: +8.06%
EPS: +8.47%
Free cash flow: +69.5%
Total debt: +8.81%

Quarter to July 2026, against a year earlier

171.89 5.28 −2.98%

Follow A

Alert me

Market cap: $48.4B
P/E: 33.8×
Fwd P/E: 34.1×
Dividend yield: 0.59%
F-score: 5/9
Altman Z: 5.46
Beneish M: −2.46
Dividend safety: 86/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Agilent Technologies, Inc. (A) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by segment, and margins
Agilent CrossLab	2,908	41.85%
Life Sciences and Diagnostics Markets	2,726	39.23%
Applied Markets	1,314	18.91%
Gross margin		52.43%
Operating margin		21.29%
Pre-tax margin		20.65%

Revenue by product or service $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2015	FY2014	FY2013
Non-Instrumentation and Other	4,521 65.07%	4,156 63.84%	4,091 59.87%	3,941 57.55%	3,662 57.95%	3,090 57.88%	3,013 58.36%	—	—	—	—	—
Instrumentation	2,427 34.93%	2,354 36.16%	2,742 40.13%	2,907 42.45%	2,657 42.05%	2,249 42.12%	2,150 41.64%	—	—	1,827 45.25%	1,839 45.43%	1,802 46.28%
Analytical Lab Services	—	—	—	—	—	—	—	—	—	843 20.88%	831 20.53%	768 19.72%
Diagnostics and genomics solutions	—	—	—	—	—	—	—	—	—	662 16.39%	663 16.38%	635 16.31%
Analytical lab consumables	—	—	—	—	—	—	—	—	—	489 12.11%	476 11.76%	456 11.71%
Informatics and other	—	—	—	—	—	—	—	—	—	217 5.37%	239 5.90%	233 5.98%
Also reported: a second breakdown of the same revenue
Product	4,944 71.16%	4,672 71.77%	5,051 73.92%	5,187 75.74%	4,756 75.27%	3,993 74.79%	3,877 75.09%	3,746 76.23%	3,397 75.96%	—	—	—
Services and Other	2,004 28.84%	1,838 28.23%	1,782 26.08%	1,661 24.26%	1,563 24.73%	1,346 25.21%	1,286 24.91%	1,168 23.77%	1,075 24.04%	—	—	—
Revenue	6,948	6,510	6,833	6,848	6,319	5,339	5,163	4,914	4,472	4,038	4,048	3,894

Gross profit by product or service $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2015	FY2014	FY2013
Product	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Services and Other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Gross profit	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
Agilent CrossLab	2,908 41.85%	2,747 42.20%	2,656 38.87%	1,452 21.20%	1,360 21.52%	1,177 22.05%	1,840 35.64%	1,701 34.62%	1,531 34.24%	1,420 33.79%	1,330 32.94%	1,307 32.29%	1,224 31.43%	3,315 48.34%	3,316 50.13%	2,784 51.14%	2,418 53.96%
Life Sciences and Diagnostics Markets	2,726 39.23%	2,466 37.88%	2,780 40.68%	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Applied Markets	1,314 18.91%	1,297 19.92%	1,397 20.44%	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Life Sciences and Applied Markets	—	—	—	3,630 53.01%	3,663 57.97%	3,115 58.34%	2,302 44.59%	2,270 46.19%	2,081 46.53%	1,992 47.41%	2,046 50.67%	2,078 51.33%	2,035 52.26%	1,984 28.93%	1,792 27.09%	—	—
Diagnostics and Genomics	—	—	—	1,766 25.79%	1,296 20.51%	1,047 19.61%	1,021 19.78%	943 19.19%	860 19.23%	790 18.80%	662 16.39%	663 16.38%	—	—	—	253 4.65%	—
Chemical Analysis	—	—	—	—	—	—	—	—	—	—	—	—	635 16.31%	1,559 22.73%	1,518 22.95%	1,196 21.97%	844 18.84%
Life Sciences	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1,211 22.24%	1,219 27.20%
Segment Total	—	—	—	—	—	5,339	5,163	4,914	4,472	4,202	4,038	4,048	3,894	6,858	6,626	5,444	4,481
Revenue	6,948	6,510	6,833	6,848	6,319	5,339	5,163	4,914	4,472	4,202	4,038	4,048	3,894	6,858	6,615	5,444	4,481

Operating income by segment $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
Agilent CrossLab	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Life Sciences and Diagnostics Markets	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Applied Markets	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Life Sciences and Applied Markets	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Diagnostics and Genomics	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Chemical Analysis	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Life Sciences	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Corporate and other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Operating income	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012
Americas	2,806 40.39%	2,573 39.52%	2,732 39.98%	2,682 39.16%	2,404 38.04%	1,968 36.86%	1,861 36.04%	—	—	—	—	—	—	—
Asia Pacific	2,219 31.94%	2,167 33.29%	2,347 34.35%	2,467 36.03%	2,227 35.24%	1,928 36.11%	1,861 36.04%	—	—	—	—	—	—	—
Europe	1,923 27.68%	1,770 27.19%	1,754 25.67%	1,699 24.81%	1,688 26.71%	1,443 27.03%	1,441 27.91%	—	—	—	—	—	—	—
Japan	—	—	—	—	—	—	—	—	—	—	—	—	—	716 10.44%
Also reported: a second breakdown of the same revenue
Rest Of World	3,382 48.68%	3,047 46.80%	3,040 44.49%	2,964 43.28%	2,887 45.69%	2,500 46.83%	2,525 48.91%	2,485 50.57%	2,258 50.49%	2,112 50.26%	2,131 52.77%	2,486 61.41%	2,198 56.45%	2,846 41.50%
UNITED STATES	2,342 33.71%	2,246 34.50%	2,410 35.27%	2,385 34.83%	2,159 34.17%	1,752 32.82%	1,619 31.36%	1,414 28.77%	1,314 29.38%	1,251 29.77%	1,214 30.06%	1,019 25.17%	1,077 27.66%	2,218 32.34%
CHINA Including Hong Kong	1,224 17.62%	1,217 18.69%	1,383 20.24%	1,499 21.89%	1,273 20.15%	1,087 20.36%	1,019 19.74%	1,015 20.66%	900 20.13%	839 19.97%	693 17.16%	543 13.41%	619 15.90%	1,078 15.72%
Revenue	6,948	6,510	6,833	6,848	6,319	5,339	5,163	4,914	4,472	4,202	4,038	4,048	3,894	6,858

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
Remaining performance obligations	Q4 FY2025	$437.0M	$409.0M	+6.85%

	Q4 FY2025	Q4 FY2024	Q4 FY2023	Q4 FY2022	Q4 FY2021	Q4 FY2020	Q1 FY2020	Q4 FY2019	Q3 FY2019	Q2 FY2019	Q1 FY2019
Remaining performance obligations	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.